|
|
Post by JHam on Dec 5, 2014 12:31:07 GMT
ir.oncosec.com/company-news/detail/1684OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014 Download PDF SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a corporate update conference call on Tuesday, December 9, 2014 at 10 AM ET. The call will cover recent milestone achievements and corporate and clinical development strategies, but will not address the company’s results of operations or financial condition for a completed quarterly or annual fiscal period. To participate in the call, dial toll-free (855) 801-3670 in the U.S. and Canada or (804) 681-3878 outside the U.S. and Canada and enter conference ID #48289768. A replay of the conference call will be available 2 hours after the call’s completion through January 23, 2015. To access this recording, dial (855) 859-2056in the U.S. and Canada or (404) 537-3406outside the U.S. and Canada and enter conference ID #48289768. To listen to the conference call, dial in approximately ten minutes before the scheduled call. An archived replay of the call will also be available through the investors page at www.oncosec.com. Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to investors@oncosec.com. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact OncoSec's Investor Relations department by phone at (855) 662-6732or by email at investors@oncosec.com
|
|
|
|
Post by JHam on Dec 5, 2014 12:43:11 GMT
So this is really interesting to me for a few reasons. First, I believe this will be the first conference call they have ever hosted. The fact that they will not be discussing earnings, only discussing milestone achievements, and corporate and clinical development strategies is also pretty interesting. I think this strongly suggests we will be getting a PR on Monday announcing the new indication, and perhaps even a PR on Tuesday announcing MCC data (or vice versa). Why have a call discussing the milestone achievements of two major ones haven't been announced yet? I could be wrong, but it makes sense. If they don't announce one of those two items (or both), then I think it indicates the Phase 2 final they are going to present today is going to be very good. Or, it could be a combination of all three things happening. How's that for positive thinking?  |
|
|
|
Post by jckrdu on Dec 5, 2014 12:53:25 GMT
So this is really interesting to me for a few reasons. First, I believe this will be the first conference call they have ever hosted. The fact that they will not be discussing earnings, only discussing milestone achievements, and corporate and clinical development strategies is also pretty interesting. I think this strongly suggests we will be getting a PR on Monday announcing the new indication, and perhaps even a PR on Tuesday announcing MCC data (or vice versa). Why have a call discussing the milestone achievements of two major ones haven't been announced yet? I could be wrong, but it makes sense. If they don't announce one of those two items (or both), then I think it indicates the Phase 2 final they are going to present today is going to be very good. Or, it could be a combination of all three things happening. How's that for positive thinking? Agree JHam, especially on news of the new indication being PR'd before the call. They stated "The call will cover recent milestone achievements and corporate and clinical development strategies". So how can they discuss their clinical development strategy of going after the new indication if they haven't disclosed what that new indication is before this call? Sitting tight with my shares until Tuesday morning. May sell a little before the call based on news released prior. |
|
|
|
Post by JHam on Dec 5, 2014 13:08:57 GMT
So this is really interesting to me for a few reasons. First, I believe this will be the first conference call they have ever hosted. The fact that they will not be discussing earnings, only discussing milestone achievements, and corporate and clinical development strategies is also pretty interesting. I think this strongly suggests we will be getting a PR on Monday announcing the new indication, and perhaps even a PR on Tuesday announcing MCC data (or vice versa). Why have a call discussing the milestone achievements of two major ones haven't been announced yet? I could be wrong, but it makes sense. If they don't announce one of those two items (or both), then I think it indicates the Phase 2 final they are going to present today is going to be very good. Or, it could be a combination of all three things happening. How's that for positive thinking? Agree JHam, especially on news of the new indication being PR'd before the call. They stated "The call will cover recent milestone achievements and corporate and clinical development strategies". So how can they discuss their clinical development strategy of going after the new indication if they haven't disclosed what that new indication is before this call? Sitting tight with my shares until Tuesday morning. May sell a little before the call based on news released prior. A possibility on the corporate strategy side is that they finally announce their intention to get listed on the Nasdaq, which may include doing a reverse split. Despite Dhillon saying in the past that he thinks they can do it "organically". |
|
|
|
Post by hophead on Dec 5, 2014 13:10:08 GMT
Nice! should hopefully see a rise into this cc one would think. Agree with you jck, that taking some shares off the table prior to the cc might be a smart move. We all know how pps usually reacts after these calls are finished...
|
|
|
|
Post by JHam on Dec 5, 2014 13:40:25 GMT
So this is really interesting to me for a few reasons. First, I believe this will be the first conference call they have ever hosted. The fact that they will not be discussing earnings, only discussing milestone achievements, and corporate and clinical development strategies is also pretty interesting. I think this strongly suggests we will be getting a PR on Monday announcing the new indication, and perhaps even a PR on Tuesday announcing MCC data (or vice versa). Why have a call discussing the milestone achievements of two major ones haven't been announced yet? I could be wrong, but it makes sense. If they don't announce one of those two items (or both), then I think it indicates the Phase 2 final they are going to present today is going to be very good. Or, it could be a combination of all three things happening. How's that for positive thinking? Agree JHam, especially on news of the new indication being PR'd before the call. They stated "The call will cover recent milestone achievements and corporate and clinical development strategies". So how can they discuss their clinical development strategy of going after the new indication if they haven't disclosed what that new indication is before this call? Sitting tight with my shares until Tuesday morning. May sell a little before the call based on news released prior. I am taking the same approach with selling. I may shave a bit off the top prior to the call. Especially if it reaches $.65 again. That was my original trigger price for my trading shares, but since it jumped up so fast I got greedy and of course it went back down. |
|
|
|
Post by JHam on Dec 9, 2014 4:38:43 GMT
One thing being discussed at the Google Group regarding today's call is the possibility of ONCS announcing they are going to scrap the MCC program. Apparently it was written in a filing way back before I was interested in this company that they may consider doing this even if results are positive in order to focus resources on melanoma only in the skin cancer program. It would actually make sense since it would save some cash and since the MCC is very small.
|
|
|
|
Post by lcd on Dec 9, 2014 15:11:33 GMT
I had hoped to call in but am not able to hear it live. The market sure isn't optimistic about the recent news but hopefully it is an informative call.
|
|
|
|
Post by JHam on Dec 9, 2014 15:48:55 GMT
Just listened to the call. It was about 40 mins long. They talked about so much it is going to be tough to recap. The biggest item is that they are stopping the MCC trial. Overall, it was a really good call. ONCS is moving full steam ahead and listening to them talk about everything was very exciting. Robert Pierce is a genius and you get the sense from listening that he knows what they are doing will work. I am going to have to re-listen to the call again before being able to give a recap.
Oh, they did say that they cannot disclose their relationship with Merck, which to me indicates they have other stuff going on.
|
|
|
|
Post by JHam on Dec 9, 2014 15:53:28 GMT
They also confirmed that they wanted to go the monotherapy route for Head and Neck to prove the hypothesis that Immunopulse will increase TIL in a tumor. Once they do, they will go into a combo therapy trial.
|
|
|
|
Post by JHam on Dec 10, 2014 1:43:54 GMT
Here are the names and positions of the 4 people who called in. All of them asked multiple questions and were very well informed about the science and asked really intelligent questions:
1. Jason Kolbert (someone called on his behalf)-- stock analyst at maxim
2. Tom Schraeder-- managing director at stifil
3. Raul something-- couldn't identify
4. Reni Benjamin-- stock analyst at H.C. Wainwright
|
|
|
|
Post by happyjawa on Dec 10, 2014 2:30:06 GMT
Here are the names and positions of the 4 people who called in. All of them asked multiple questions and were very well informed about the science and asked really intelligent questions: 1. Jason Kolbert (someone called on his behalf)-- stock analyst at maxim 2. Tom Schraeder-- managing director at stifil 3. Raul something-- couldn't identify 4. Reni Benjamin-- stock analyst at H.C. Wainwright Dr. Pierce has a following that rivals Dr. Lanza, and we're getting questions during CCs from Jason Kolbert. The Google group is a nice touch, too. ONCS is quickly becoming the new OCAT. When am I going to learn to stick to blue chips? :-) |
|
|
|
Post by JHam on Dec 10, 2014 8:19:54 GMT
Here are the names and positions of the 4 people who called in. All of them asked multiple questions and were very well informed about the science and asked really intelligent questions: 1. Jason Kolbert (someone called on his behalf)-- stock analyst at maxim 2. Tom Schraeder-- managing director at stifil 3. Raul something-- couldn't identify 4. Reni Benjamin-- stock analyst at H.C. Wainwright Dr. Pierce has a following that rivals Dr. Lanza, and we're getting questions during CCs from Jason Kolbert. The Google group is a nice touch, too. ONCS is quickly becoming the new OCAT. When am I going to learn to stick to blue chips? :-) I know right. ONCS and OCAT are torn from the same cloth. The big difference though, and why I let myself get caught up in the kool-aide a bit, is because ONCS is so much further along than OCAT. Four Phase 2 trials (MCC, Melanoma, Combination, Head & Neck, although I guess melanoma and the combination are now the same trial), have already done their huge raise, and have made several key partnerships including a collaboration with Merck. I guess one could argue that OCAT has less shares and is about to up-list though. By the way, about the MCC trial. They haven't done away with it altogether. They will release the data this month. They just don't see the reason to pursue it any more as a monotherapy. If the combination trial is successful then they will go forward with MCC in combination. |
|
